The Wood on Clinuvel

By Dylan Bushell-Embling
Tuesday, 08 July, 2008

Clinuvel Pharmaceuticals [ASX: CUV] has set in train its plan to add international expertise to its board, with the appointment of a new non-executive director.

Jack Wood was appointed to the position today. Wood currently sits on the board of two Canadian biotechnology companies, Engene and QLT.

He also has experience in the Australian pharmaceutical sector, including eight years serving in various executive positons at CSL from 1992-2000.

Clinuvel is seeking international expertise in anticipation of the commercialisation of its photoprotective drug afamelanotide (CUV1647).

Content from other channels on our network

Enabling OT continuous monitoring

Ghost Bat a major milestone for local defence manufacturing

Central Coast Council completes first remote sewer inspection

From smart to vulnerable: The hidden costs of the digitalisation of utilities

Copper SA partners with Aurizon for copper logistics

GNT shows how plant-based colours can liven up snacks

Getting a handle on a shrink bag for turkey

Six on the shelf: from frozen snacks to GF treats

Visibly conveying freshly roasted coffee direct to the consumer

Sobering up with the latest wine trends

Urinary incontinence and cardiovascular disease risk in women

Pharmacist distraction during dispensing — extent and sources

Ambulance ramping — its "very real potential human consequences"

Could this game wave goodbye to nerve pain?

Inaugural Hospital + Healthcare Excellence Awards — nominations open

The Wood on Clinuvel

Organoid platform enables closer study of bat-borne viruses

Global study finds 250 genes linked to OCD

TGA approves therapy for paediatric growth hormone deficiency

Content from other channels on our network